Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization

被引:7
|
作者
Ventura, Yossi [1 ,2 ]
Carr, Brian I. [3 ]
Kori, Issac [4 ]
Guerra, Vito [5 ]
Shibolet, Oren [1 ,2 ]
机构
[1] Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol & Hepatol, Liver Unit, 14 Weizman St, IL-62431 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Dokuz Eylul Univ, Izmir Biomed & Genome Ctr, TR-35340 Izmir, Turkey
[4] Tel Aviv Med Ctr & Sch Med, Div Imaging, Intervent Radiol, IL-62431 Tel Aviv, Israel
[5] IRCCS Bellis, Dept Clin Trials & Epidemiol, I-70013 Castellana Grotte, Italy
关键词
Hepatocellular carcinoma; Aggressiveness index; Liver function; Transarterial chemoembolization; Survival; GAMMA-GLUTAMYL-TRANSPEPTIDASE; PREDICT SURVIVAL; PROGNOSTIC VALUE; SCORES; EMBOLIZATION; INDEX;
D O I
10.3748/wjg.v24.i15.1641
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To investigate novel predictors of survival in hepatocellular carcinoma (HCC) patients following transarterial chemoembolization (TACE). METHODS One hundred sixty seven patients with un-resectable HCC were retrospectively analyzed to identify factors that might contribute to their HCC biology and aggressiveness. We correlated routine laboratory results (total bilirubin, AST, ALKP, GGTP, albumin etc.) to maximum tumor diameter, number of tumor nodules, portal vein thrombosis and blood alpha-fetoprotein levels. These 4 parameters were previously combined to form an aggressiveness index (AgI). We used The Wilcoxon ranksum (Mann-Whitney), to test the correlation between the AgI categories and liver function parameters. The Cox proportional hazards model was applied to evaluate the categories of AgI associated with overall survival. RESULTS The AgI was strongly correlated with survival in this novel patient population. Three year survival probability for AgI > or < 4 was 42.4% vs 61.8%; p < 0.0863 respectively. Several factors independently correlated with AgI using univariate multiple logistic regression of AgI with 8 laboratory parameters. Lower albumin levels had an OR of 2.56 (95% CI: 1.120-5.863 p < 0.026), elevated Alkaline phosphatase and gamma glutamyl transpeptidase (GGTP) had ORs of 1.01 (95% CI: 1.003-1.026, p < 0.017) and 0.99 (95% CI: 0.99-1.00, p < 0.053) respectively. In a Cox proportional hazard model combining mortality for AgI score and liver function parameters, only GGTP levels and the AgI were independently associated with survival. An AgI > 4 had HR for mortality of 2.18 (95% CI: 1.108-4.310, p < 0.024). GGTP's single unit change had a HR for mortality of 1.003 (95% CI: 1.001-1.006, p < 0.016). These were considered in the final multivariate model with the total cohort. An AgI > 4 had a HR for mortality of 2.26 (95% CI: 1.184-4.327, p < 0.016). GGTP had a HR of 1.003 (95% CI: 1.001-1.004, p < 0.001). CONCLUSION Our study validates the AgI in a new population with un-resectable HCC patients undergoing TACE. The analysis establishes a correlation between GGTP and the AgI.
引用
收藏
页码:1641 / 1649
页数:9
相关论文
共 50 条
  • [41] Transarterial radioembolization versus chemoembolization for hepatocellular carcinoma: a meta-analysis
    Lu, Wenxiao
    Zhang, Tongsheng
    Xia, Fengfei
    Huang, Xiangzhong
    Gao, Fulei
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [42] Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization
    Kim, Hyung-Don
    Shim, Ju Hyun
    Kim, Gi-Ae
    Shin, Yong Moon
    Yu, Eunsil
    Lee, Sung-Gyu
    Lee, Danbi
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Chung, Young-Hwa
    Lee, Yung Sang
    JOURNAL OF HEPATOLOGY, 2015, 62 (05) : 1076 - 1084
  • [43] Preoperative Transarterial Chemoembolization for Hepatocellular Carcinoma
    Kishi, Yoji
    Saiura, Akio
    Yamamoto, Junji
    Koga, Rintaro
    Seki, Makoto
    Morimura, Ryo
    Yoshioka, Ryuji
    Kokudo, Norihiro
    Yamaguchi, Toshiharu
    HEPATO-GASTROENTEROLOGY, 2012, 59 (119) : 2295 - 2299
  • [44] Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization
    Ho, Shu-Yein
    Liu, Po-Hong
    Hsu, Chia-Yang
    Ko, Chih-Chieh
    Huang, Yi-Hsiang
    Su, Chien-Wei
    Lee, Rheun-Chuan
    Tsai, Ping-Hsing
    Hou, Ming-Chih
    Huo, Teh-Ia
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (11) : 3196 - 3203
  • [45] Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis
    Hu, M-D.
    Jia, L-H.
    Liu, H-B.
    Zhang, K-H.
    Guo, G-H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (01) : 64 - 74
  • [46] Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
    Cho, Eun Ju
    Yu, Su Jong
    Lee, Yun Bin
    Lee, Jeong-Hoon
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    DIAGNOSTICS, 2022, 12 (05)
  • [47] Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis
    Liao, Mingheng
    Zhu, Zexin
    Wang, Haichuan
    Huang, Jiwei
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (6-7) : 624 - 634
  • [48] Selective and sequential transarterial chemoembolization: Survival in patients with hepatocellular carcinoma
    Antoch, Gerald
    Roelle, Grit
    Ladd, Susanne C.
    Kuehl, Hilmar
    Heusner, Till A.
    Sotiropoulos, Georgios C.
    Hilgard, Philip
    Forsting, Michael
    Verhagen, Ruediger
    EUROPEAN JOURNAL OF RADIOLOGY, 2012, 81 (09) : 2290 - 2297
  • [49] Is transarterial chemoembolization an option for all patients with unresectable hepatocellular carcinoma?
    Burroughs, Andrew
    Samonakis, Dirnitrios
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2004, 1 (02): : 78 - 79
  • [50] Transarterial chemoembolization of hepatocellular carcinoma
    Huppert, Peter
    RADIOLOGE, 2022, 62 (03): : 225 - 233